Trial Profile
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2023
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms TARGET-HBV
- 26 Oct 2022 Status changed from active, no longer recruiting to recruiting.
- 12 Oct 2021 Planned number of patients changed from 500 to 5000.
- 12 Oct 2021 Planned End Date changed from 1 Jan 2023 to 1 Jan 2026.